Navigation Links
Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
Date:10/24/2009

SAN DIEGO, Oct. 24 /PRNewswire-FirstCall/ -- Orexigen® ( )Therapeutics, Inc (Nasdaq: OREX) today announced new data from the COR-I, COR-II and COR-Diabetes trials for Contrave® (bupropion SR/ naltrexone SR) to expand on top-line results announced in July. Contrave is the first of the Company's two late stage candidates for the treatment of obesity. These data were presented during a panel discussion at the 27th Annual Scientific Meeting of The Obesity Society.

These new data show that after completing 56 weeks of therapy with Contrave32:

  • Approximately 34-48% of patients lost at least 10% of their baseline body weight and approximately 17-23% lost at least 15%;
  • Obese patients classified as higher risk for developing cardiovascular disease and diabetes demonstrated significant improvement in markers of cardiometabolic risk such as waist circumference, HDL, and triglycerides;
  • Patients with type 2 diabetes taking Contrave who began the trial with a hemoglobin A1c (HbA1c) level greater than 8% saw a mean HbA1c reduction of 1.1%, which was highly statistically significant compared to placebo;
  • Patients reported an increased ability to control their eating and resist food cravings; and
  • There was no evidence of increased abuse liability.

"These data show that Contrave provides obese patients with meaningful reduction in weight and improvement in important markers of cardiometabolic risk, with even greater improvement seen in patients at higher risk," said Dennis Kim, M.D., Senior Vice President of Medical Affairs. "Results also illustrate the robust glycemic benefit of Contrave in patients who have poorly controlled diabetes, as defined by a hemoglobin A1C level greater than 8.0. These patients experienced a clinically meaningful A1C reduction of 1.1% fro
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
4. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
5. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
6. Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
7. Orexigen(R) Therapeutics Prices Public Offering of Common Stock
8. Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
9. Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients
10. Prime Therapeutics Receives TIPPS Certification
11. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... According to a new market research report “Internet ... (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, RFID), Application Vertical (Building ... & Geography - Global Trends & Forecasts to 2014 ... was worth $1029.5 Billion in 2013, and is expected ... CAGR of 4.08% from 2014 to 2020. , ...
(Date:7/11/2014)... The Miriam Hospital have found that people with ... rates of smoking than those without mobility impairments. ... to attempt quitting than those without mobility impairments, ... for this population. The study and its findings ... the American Journal of Public Health . ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, 2014 (HealthDay ... worldwide scourge of dengue fever was somewhat successful in a ... dengue fever in 56 percent of the 10,000 kids who ... than 88 percent of them from severe disease. In the ... death. "This vaccine has already proven to be safe," ...
(Date:7/11/2014)... 2014 Last month Watkins Insurance Group ... joins the agency as a specialist in insurance and ... a Bachelor’s Degree in Business Administration from Texas State ... will manage everything from performance and payment bonds, license ... specialized needs for those in the asphalt supplier industry. ...
Breaking Medicine News(10 mins):Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3
... 3 The following is being issued by The American ... by federally funded organizations operating in every state has had ... during a period when hospital performance improved faster than outpatient ... The annual National Healthcare Quality Report, just released by the ...
... treatment or not, study finds , WEDNESDAY, June 3 ... before a mammogram doesn,t lower the likelihood of being ... than 1,700 women aged 45 to 80 has found. ... women,s breasts -- and make mammograms harder to read," ...
... PLYMOUTH MEETING, Pa., June 3 /PRNewswire-Asia-FirstCall/ -- ... or the "Company") today announced,that it will be featured ... conference call series to discuss the impact of,China Healthcare ... will be hosted by Ding Ding, Ph.D., SIG,s senior ...
... , -- Record non-infant formula nutritional sales of $9.8 million ... Earnings per share of $0.33, an increase of 20% over last ... million (Year-to-date operating cash flow of $26 million) , -- Full ... pre-tax earnings growth of 10% to 15% over fiscal 2008 ...
... IMAGINE Software, a leading provider of ... within the IMAGINEradiology(TM) practice management system at IMAGINE,s 2009 ... , , The system received a number ... deployment and maintenance distribution through application virtualization; "I-Connect," ...
... of Obama and His Agenda; Jon Stewart Bests Stephen Colbert, ... 3 Progressives gathered at this week,s "America,s Future Now" ... ,s first 100 days, but they are very focused on ... straw poll of participants conducted by Greenberg Quinlan Rosner Research ...
Cached Medicine News:Health News:QIO Support Accelerates Hospital Improvement in Heart Care, Researchers Find 2Health News:Pausing Hormone Therapy Doesn't Cut Mammogram Recalls 2Health News:BMP Sunstone to be Featured on SIG's 'China Healthcare On Call' Conference Call Series 2Health News:Martek Announces Second Quarter 2009 Financial Results 2Health News:Martek Announces Second Quarter 2009 Financial Results 3Health News:Martek Announces Second Quarter 2009 Financial Results 4Health News:Martek Announces Second Quarter 2009 Financial Results 5Health News:Martek Announces Second Quarter 2009 Financial Results 6Health News:Martek Announces Second Quarter 2009 Financial Results 7Health News:Martek Announces Second Quarter 2009 Financial Results 8Health News:Martek Announces Second Quarter 2009 Financial Results 9Health News:Martek Announces Second Quarter 2009 Financial Results 10Health News:Martek Announces Second Quarter 2009 Financial Results 11Health News:Martek Announces Second Quarter 2009 Financial Results 12Health News:IMAGINE Software Unveils Advanced IMAGINEradiology(TM) Features 2Health News:'America's Future Now' Straw Poll: Progressives See Health Care Reform With Public Option As Top Priority 2
(Date:7/11/2014)... 2014 According to a new ... Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - ... 2013-2019" the global endoscopy devices market was valued at ... grow at a CAGR of 6.8% from 2013 to ... billion in 2019. Browse the full Endoscopy ...
(Date:7/10/2014)... India , July 11, 2014  Major ... treatment of cancer are being highlighted in a ... Mumbai from 10-12 July, 2014.  Renowned national ... to share best practices and exchange knowledge on ... precise, accurate and efficient. The ...
(Date:7/10/2014)...  RESMED INC. (NYSE: RMD ) today announced ... ended June 30, 2014 results on Thursday, July 31, 2014, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Soligenix, Inc. (OTC Bulletin Board: SNGX ) ... today that it has appointed Kevin Horgan, MD, as ... Horgan is a board-certified gastroenterologist with a research background ... patients with inflammatory bowel disease, including graft-versus-host disease (GVHD). ...
... JOLLA, Calif., Feb. 1, 2011 Transdel Pharmaceuticals, ... a specialty pharmaceutical company focused on developing topically ... announced that the Company has been exploring strategic alternatives ... American MedTech Advisors and ESC Advisors, a division ...
Cached Medicine Technology:Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 2Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 3Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 4Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3
... operating lamp offers a light output of ... field diameter. The innovative lamp also produces ... additional advantage of the fascinating gas discharge ... is top technology, setting new standards with ...
The Next Generation in Single Lamp Technology, Advanced Optics & Reflector Design, Extended Depth of Field, 54" Useable Column of Light, High Intensity, Cool Beam Temperature...
... an interventional guidance device that uses ... the accuracy of computed tomography (CT)-guided ... accuracy, SimpliCT® also has the potential ... puncture procedures including biopsies and fluid ...
Up-tapered output compresses NA to give low NA fiber performance on high NA fiber stock....
Medicine Products: